FDA Announces Delayed Enforcement of DSCSA to 2024
Pharmacy Times
AUGUST 28, 2023
The start date of the package-level electronic tracking system will shift from November 27, 2023 to November 27, 2024.
Pharmacy Times
AUGUST 28, 2023
The start date of the package-level electronic tracking system will shift from November 27, 2023 to November 27, 2024.
The FDA Law Blog
FEBRUARY 2, 2025
By Sara M Keup In reviewing some new 2025 pharmacy rules/laws a couple interesting changes caught this bloggers attention: As of December 30, 2024, Missouri has rolled out new rules related to prescription drug delivery requirements. The California Board of Pharmacy updated many of the application forms and guidelines in late 2024.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
OCTOBER 3, 2024
Preparing for the impact of EU GMP Annex 1 on primary packaging Niamh Bissett and Dr Ana Kuschel West Pharmaceutical Services, Inc. The post <em>European Pharmaceutical Review </em> Issue 4 2024 appeared first on European Pharmaceutical Review. Login or create an account to download your copy of our Issue now!
European Pharmaceutical Review
JANUARY 25, 2024
Draft guidance published by the US Food and Drug Administration (FDA) in December 2023, discussed quality considerations for topical ophthalmic drug products, including key considerations for extractables and leachables (E&L) testing. Ophthalmic drug products should be evaluated for extractables and leachables, FDA asserted.
STAT
JULY 11, 2024
This calls for celebration with a cup of stimulation, and we are opening a new package of blueberry muffin for the occasion. Novo said it does not expect to be able to fulfill the requests during 2024, delaying the program for several months at least. What is upon us right now, however, is our ever-growing to-do list. Sound familiar?
The FDA Law Blog
AUGUST 27, 2023
However, FDA recognizes that some “technical and operational issues,” including those involving downstream trading partners and other “affected stakeholders,” may not be fully resolved by the deadline. So what is FDA going to do? By Karla L. Drug manufacturers have had electronic systems in place since 2017.
European Pharmaceutical Review
APRIL 26, 2024
Recent biosimilar developments In February 2024, the EMA’s Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion for Pyzchiva as a biosimilar to treat the autoimmune condition plaque psoriasis.
Let's personalize your content